Boehringer and Lilly launch new trial looking at CV impact of Jardiance

16 April 2018

Privately-held German firm Boehringer Ingelheim and Eli Lilly (NYSE: LLY) are to collaborate with the University of Oxford, UK, to investigate the effects of the SGLT2 inhibitor Jardiance (empagliflozin) on certain kidney disease patients.

Lilly and family-owned Boehringer won approval for the therapy in 2014, and have continued to pursue approvals in other indications. Jardiance has continued to perform well in this therapeutic area.

The outcomes study, dubbed EMPA-KIDNEY, will look at the progression of kidney disease and the occurrence of cardiovascular death in adults with established chronic kidney disease with and without diabetes.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK